Standpoint Research downgrades Biogen Idec (Nasdaq: BIIB) from Buy to Hold.

The firm comments, "Our January 19, 2010 recommendation is now ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE